Brokerage Firm Rating on Sequenom (SQNM)

Sequenom (SQNM) : The consensus on Sequenom (SQNM) based on 4 analyst recommendation on the company stock is 3, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Sequenom (SQNM) : The consensus price target for Sequenom (SQNM) is $1.35 for the short term with a standard deviation of $0.91. The most optimist securities analyst among the 3 who monitor the stock believes that the stock can reach $2, however, the pessimist price target for the company is $1.


Company shares have received an average consensus rating of Hold for the current week Sequenom (NASDAQ:SQNM): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.37 and $2.37 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.38. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.38, notching a gain of 0.42% for the day. The total traded volume was 2,603,745 . The stock had closed at $2.37 on the previous day.

In a related news, Beaver Carolyn, CFO of Sequenom Inc, had purchased 30,000 shares on June 10, 2016. The total value of the transaction was $33,000. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.